If you have follicular lymphoma and have been treated with obinituzumab (Gazyva) you can help by completing our survey.
Lymphoma Canada is preparing a submission for the panCanadian Oncology Drug Review (pCODR) for:
Obinituzumab in combination with chemotherapy, followed by obinutuzumab maintenance, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab containing regimen.
You can help by completing our survey, which will provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Friday, October 28th and should only take 10 minutes of your time.
You may access the survey by clicking the link below.
